{"name":"Gruppo Italiano Terapie Innovative nei Linfomi","slug":"gruppo-italiano-terapie-innovative-nei-linfomi","ticker":"","exchange":"","domain":"","description":"Gruppo Italiano Terapie Innovative nei Linfomi (GITIL) is an Italian biopharmaceutical company focused on developing innovative therapies for lymphoma. The company's lead product, Rituximab-HDS, is currently in Phase 3 clinical trials. GITIL aims to improve patient outcomes through targeted and personalized treatment approaches.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rituximab-HDS","genericName":"Rituximab-HDS","slug":"rituximab-hds","indication":"B-cell non-Hodgkin lymphoma (various subtypes)","status":"phase_3"}]}],"pipeline":[{"name":"Rituximab-HDS","genericName":"Rituximab-HDS","slug":"rituximab-hds","phase":"phase_3","mechanism":"Rituximab-HDS is a high-dose formulation of rituximab, a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen.","indications":["B-cell non-Hodgkin lymphoma (various subtypes)","Lymphoid malignancies expressing CD20"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}